|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li L and Ma BB: Colorectal cancer in
Chinese patients: Current and emerging treatment options. Onco
Targets Ther. 7:1817–1828. 2014.PubMed/NCBI
|
|
3
|
Loree JM and Kopetz S: Recent developments
in the treatment of metastatic colorectal cancer. Ther Adv Med
Oncol. 9:551–564. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Boland PM and Ma WW: Immunotherapy for
colorectal cancer. Cancers. 9:pii: E502017. View Article : Google Scholar
|
|
5
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ha M and Kim VN: Regulation of microRNA
biogenesis. Nat Rev Mol Cell Biol. 15:509–524. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
King TD, Suto MJ and Li Y: The
Wnt/β-catenin signaling pathway: A potential therapeutic target in
the treatment of triple negative breast cancer. J Cell Biochem.
113:13–18. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Magee P, Shi L and Garofalo M: Role of
microRNAs in chemoresistance. Ann Transl Med. 3:3322015.PubMed/NCBI
|
|
10
|
Zhao C, Wang G, Zhu Y, Li X, Yan F, Zhang
C, Huang X and Zhang Y: Aberrant regulation of miR-15b in human
malignant tumors and its effects on the hallmarks of cancer. Tumour
Biol. 37:177–183. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang WL, Zhang JH, Wu XZ, Yan T and Lv W:
miR-15b promotes epithelial-mesenchymal transition by inhibiting
SMURF2 in pancreatic cancer. Int J Oncol. 47:1043–1053. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lovat F, Fassan M, Gasparini P, Rizzotto
L, Cascione L, Pizzi M, Vicentini C, Balatti V, Palmieri D,
Costinean S and Croce CM: miR-15b/16-2 deletion promotes B-cell
malignancies. Proc Natl Acad Sci USA. 112:pp. 11636–11641. 2015;
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhao Z, Zhang L, Yao Q and Tao Z: miR-15b
regulates cisplatin resistance and metastasis by targeting PEBP4 in
human lung adenocarcinoma cells. Cancer Gene Ther. 22:108–114.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sun L, Yao Y, Liu B, Lin Z, Lin L, Yang M,
Zhang W, Chen W, Pan C, Liu Q, et al: miR-200b and miR-15b regulate
chemotherapy-induced epithelial-mesenchymal transition in human
tongue cancer cells by targeting BMI1. Oncogene. 31:432–445. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Konishi T, Sasaki S, Watanabe T, Kitayama
J and Nagawa H: Overexpression of hRFI inhibits
5-fluorouracil-induced apoptosis in colorectal cancer cells via
activation of NF-kappaB and upregulation of BCL-2 and BCL-XL.
Oncogene. 25:3160–3169. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cimmino A, Calin GA, Fabbri M, Iorio MV,
Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, et
al: miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl
Acad Sci USA. 102:pp. 13944–13949. 2005; View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cunningham D, Allum WH, Stenning SP,
Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ,
Falk SJ, Iveson TJ, et al: Perioperative chemotherapy versus
surgery alone for resectable gastroesophageal cancer. N Engl J Med.
355:11–20. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wilson TR, Longley DB and Johnston PG:
Chemoresistance in solid tumours. Ann Oncol. 17 Suppl 10:x315–x324.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gottesman MM, Fojo T and Bates SE:
Multidrug resistance in cancer: Role of ATP-dependent transporters.
Nat Rev Cancer. 2:48–58. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Barnes MJ, Estlin EJ, Taylor GA, Aherne
GW, Hardcastle A, McGuire JJ, Calvete JA, Lunec J, Pearson AD and
Newell DR: Impact of polyglutamation on sensitivity to raltitrexed
and methotrexate in relation to drug-induced inhibition of de novo
thymidylate and purine biosynthesis in CCRF-CEM cell lines. Clin
Cancer Res. 5:2548–2558. 1999.PubMed/NCBI
|
|
22
|
Dabholkar M, Vionnet J, Bostick-Bruton F,
Yu JJ and Reed E: Messenger RNA levels of XPAC and ERCC1 in ovarian
cancer tissue correlate with response to platinum-based
chemotherapy. J Clin Invest. 94:703–708. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Amirkhah R, Farazmand A, Irfan-Maqsood M,
Wolkenhauer O and Schmitz U: The role of microRNAs in the
resistance to colorectal cancer treatments. Cell Mol Biol
(Noisy-le-grand). 61:17–23. 2015.PubMed/NCBI
|
|
24
|
Dehghanzadeh R, Jadidi-Niaragh F, Gharibi
T and Yousefi M: MicroRNA-induced drug resistance in gastric
cancer. Biomed Pharmacother. 74:191–199. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang G, Zhao R, Zhao X, Chen XI, Wang D,
Jin Y, Liu XI, Zhao CI, Zhu Y, Ren C, et al: MicroRNA-181a enhances
the chemotherapeutic sensitivity of chronic myeloid leukemia to
imatinib. Oncol Lett. 10:2835–2841. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang H, Kong W, He L, Zhao JJ, O'Donnell
JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV and Cheng JQ:
MicroRNA expression profiling in human ovarian cancer: miR-214
induces cell survival and cisplatin resistance by targeting PTEN.
Cancer Res. 68:425–433. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen X, Jiang Y, Huang Z, Li D, Chen X,
Cao M, Meng Q, Pang H, Sun L, Zhao Y and Cai L: miRNA-378 reverses
chemoresistance to cisplatin in lung adenocarcinoma cells by
targeting secreted clusterin. Sci Rep. 6:194552016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xi Y, Formentini A, Chien M, Weir DB,
Russo JJ and Ju J, Kornmann M and Ju J: Prognostic values of
microRNAs in colorectal cancer. Biomarker Insights. 2:113–121.
2006.PubMed/NCBI
|
|
29
|
Wang X, Wang J, Ma H, Zhang J and Zhou X:
Downregulation of miR-195 correlates with lymph node metastasis and
poor prognosis in colorectal cancer. Med Oncol. 29:919–927. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wu CS, Yen CJ, Chou RH, Chen JN, Huang WC,
Wu CY and Yu YL: Downregulation of microRNA-15b by hepatitis B
virus X enhances hepatocellular carcinoma proliferation via
fucosyltransferase 2-induced Globo H expression. Int J Cancer.
134:1638–1647. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kedmi M, Ben-Chetrit N, Körner C, Mancini
M, Ben-Moshe NB, Lauriola M, Lavi S, Biagioni F, Carvalho S,
Cohen-Dvashi H, et al: EGF induces microRNAs that target
suppressors of cell migration: miR-15b targets MTSS1 in breast
cancer. Sci Signal. 8:ra292015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zheng X, Chopp M, Lu Y, Buller B and Jiang
F: miR-15b and miR-152 reduce glioma cell invasion and angiogenesis
via NRP-2 and MMP-3. Cancer Lett. 329:146–154. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li J, Chen Y, Guo X, Zhou L, Jia Z, Tang
Y, Lin L, Liu W and Ren C: Inhibition of miR-15b decreases cell
migration and metastasis in colorectal cancer. Tumour Biol.
37:8765–8773. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xia L, Zhang D, Du R, Pan Y, Zhao L, Sun
S, Hong L, Liu J and Fan D: miR-15b and miR-16 modulate multidrug
resistance by targeting BCL2 in human gastric cancer cells. Int J
Cancer. 123:372–379. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rayet B and Gelinas C: Aberrant rel/nfkb
genes and activity in human cancer. Oncogene. 18:6938–6947. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Barkett M and Gilmore TD: Control of
apoptosis by Rel/NF-kappaB transcription factors. Oncogene.
18:6910–6924. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cheng Q, Lee HH, Li Y, Parks TP and Cheng
G: Upregulation of Bcl-x and Bfl-1 as a potential mechanism of
chemoresistance, which can be overcome by NF-kappaB inhibition.
Oncogene. 19:4936–4940. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xia Y, Shen S and Verma IM: NF-κB, an
active player in human cancers. Cancer Immunol Res. 2:823–830.
2014. View Article : Google Scholar : PubMed/NCBI
|
